ReviewAmerican journal of clinical dermatology2022
New Topical Therapies for Psoriasis.
Review in American journal of clinical dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 50 citations in OpenAlex.
- Harnessing Natural Compounds in Psoriasis: Targeting Cellular Pathways for Effective Therapy.Phytotherapy research : PTR · 2026Review
- Microneedle Technology in Psoriasis Management: Mechanistic Insights, Technological Innovation, Clinical Progress, and Challenges.Advanced healthcare materials · 2026Review
- Current landscape of innovative drug development and regulatory support in China.Signal transduction and targeted therapy · 2025Review
- Psoriasis.Nature reviews. Disease primers · 2025Review
- PDE4 inhibitors in psoriasis therapy: current insights and future directions.Inflammopharmacology · 2025Review
- A triple-targeting "nano-brake" remodeling the impaired immune microenvironment in skin lesions for psoriasis treatment.Materials today. Bio · 2025Article
- Tapinarof Nanogels as a Promising Therapeutic Approach.Pharmaceutics · 2025Review
- Scratching the Surface: A Comprehensive Guide to Understanding and Managing Vulvovaginal Itching.American journal of clinical dermatology · 2025Review
- Digital technologies in psoriasis management: from precision diagnosis to therapeutic innovation and holistic care.Frontiers in digital health · 2025Review
- Formulation and Evaluation of Different Nanogels of Tapinarof for Treatment of Psoriasis.Gels (Basel, Switzerland) · 2024Article
- Identification of neutrophil extracellular traps genes as potential biomarkers in psoriasis based on bioinformatics analysis.Scientific reports · 2024Article
- Cannabidiol Alleviates Imiquimod-Induced Psoriasis by Inhibiting JAK2-STAT3 in a Mouse Model.Biomedicines · 2024Article
- Calcipotriol Nanosuspension-Loaded Trilayer Dissolving Microneedle Patches for the Treatment of Psoriasis: In Vitro Delivery and In Vivo Antipsoriatic Activity Studies.Molecular pharmaceutics · 2024Article
- Small nucleolar RNA Snora73 promotes psoriasis progression by sponging miR-3074-5p and regulating PBX1 expression.Functional & integrative genomics · 2024Article
- Novel Therapeutic Hybrid Systems Using Hydrogels and Nanotechnology: A Focus on Nanoemulgels for the Treatment of Skin Diseases.Gels (Basel, Switzerland) · 2024Review
- Topical Management of Pediatric Psoriasis: A Review of New Developments and Existing Therapies.Paediatric drugs · 2024Review
- Calcipotriol and Betamethasone Dipropionate Cream Based on PAD Technology for the Treatment of Plaque Psoriasis: A Narrative Review.Dermatology and therapy · 2023Review
- Positive association between different triglyceride glucose index-related indicators and psoriasis: evidence from NHANES.Frontiers in immunology · 2023Article
- Tapinarof for the treatment of psoriasis.Dermatologic therapy · 2022Review
- A Review of the Clinical Trial Landscape in Psoriasis: An Update for Clinicians.Dermatology and therapy · 2022Review
Corrections and comments
- Erratum issued
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a chronic immune-mediated skin disease with a significant impact on patients' quality of life. Mild-to-moderate forms of the disease usually require long-term topical treatment, but prolonged use of corticosteroids and vitamin D analogues is limited by adverse effects. With further understanding of psoriasis pathogenesis, new molecules are emerging aiming to fulfil these clinical needs. Tapinarof, an aryl hydrocarbon receptor modulator, has completed a phase III study and demonstrated good efficacy results, even in long treatment courses, with a favourable safety profile. It additionally appears to have a promising remitting effect as patients presented with an average relapsing time of over 3 months. Roflumilast, a phosphodiesterase type 4 inhibitor, also underwent a phase III study with significant lesion improvement and notable pruritus management, and with no reported side effects. Roflumilast was evaluated as an option for intertriginous areas with good outcomes in a small sample, but larger trials are required. The Janus kinase-signal transducer and activator of transcription pathway has been targeted in recent clinical investigations with promising options, currently with brepocitinib pending phase IIb results. Ongoing preclinical studies involving interleukin-2 inhibition, RNA modulators and amygdalin analogues may lead to forthcoming clinical trials. New topical drugs are successfully emerging and future research comparing them to classical options will dictate their clinical role in the treatment of psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.